If you notice any swelling, severe redness, or burning sensations, discontinue use immediately
For instance, products purporting to contain retatrutide a GLP-1/GIP/glucagon triple agonist which demonstrated 24.2% weight loss at 48 weeks in Phase 2 trials have been increasing in popularity
These safety considerations prevent adverse events and help identify patients most likely to tolerate and benefit from GLP-1 therapy initiation
In the SURMOUNT-5 head-to-head trial, tirzepatide produced 20.2% average body weight loss at 72 weeks compared to 13.7% for semaglutide
Your healthcare team can perform a focused examination, obtain a rapid strep test or throat culture if indicated, and provide guidance on whether any adjustment to your diabetes or weight management regimen is necessary
For non-diabetics taking GLP agonists for other reasons most likely reducing body weight the results of this study may not be applicable as the interaction of diabetes-related inflammation, and such may be the reason for such wide-ranging GLP agonist effects. The study authors conclude that their results provide insights into the benefits and risks of GLP-1R and may be useful for informing clinical care and guiding research agendas
.png&w=828&q=100)
